Q3 EPS Estimates for AstraZeneca Increased by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Investment analysts at Zacks Research upped their Q3 2026 earnings per share estimates for shares of AstraZeneca in a research report issued on Friday, October 17th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.30 for the quarter, up from their previous estimate of $1.29. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca’s Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $5.05 EPS, Q1 2027 earnings at $1.29 EPS, Q2 2027 earnings at $1.40 EPS, Q3 2027 earnings at $1.49 EPS and FY2027 earnings at $5.75 EPS.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business’s revenue was up 16.1% on a year-over-year basis. During the same quarter last year, the business posted $1.24 EPS.

Several other brokerages also recently issued reports on AZN. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Berenberg Bank set a $97.00 target price on AstraZeneca in a research report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Trading Down 1.0%

Shares of NASDAQ AZN opened at $83.87 on Monday. The company has a market cap of $260.11 billion, a price-to-earnings ratio of 31.53, a price-to-earnings-growth ratio of 1.56 and a beta of 0.36. AstraZeneca has a 12-month low of $61.24 and a 12-month high of $86.57. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The stock’s 50 day simple moving average is $80.42 and its 200 day simple moving average is $73.97.

Hedge Funds Weigh In On AstraZeneca

Several hedge funds have recently modified their holdings of the company. Seascape Capital Management increased its position in shares of AstraZeneca by 12.0% during the 3rd quarter. Seascape Capital Management now owns 47,750 shares of the company’s stock valued at $3,663,000 after purchasing an additional 5,131 shares during the period. Miracle Mile Advisors LLC increased its position in shares of AstraZeneca by 1.8% during the 3rd quarter. Miracle Mile Advisors LLC now owns 43,412 shares of the company’s stock valued at $3,331,000 after purchasing an additional 776 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of AstraZeneca by 10.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 191,518 shares of the company’s stock valued at $16,156,000 after purchasing an additional 17,548 shares during the period. Merit Financial Group LLC increased its position in shares of AstraZeneca by 4.5% during the 3rd quarter. Merit Financial Group LLC now owns 36,494 shares of the company’s stock valued at $2,800,000 after purchasing an additional 1,565 shares during the period. Finally, Moody Lynn & Lieberson LLC acquired a new position in shares of AstraZeneca during the 3rd quarter valued at $1,943,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were given a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is currently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.